NeuroPace Inc. (NPCE)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1528287 · fiscal year ends in Dec
Closing price $13.02 on 29 Oct 2026; 52-week range $9.40 to $19.29.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $98.8M
- Revenue growth
- 11.6%
- Net income, last twelve months
- -$19.1M
- Earnings per share
- -$0.57
- Gross margin
- 79.6%
- Operating margin
- -15.3%
- Net margin
- -19.3%
- Free cash flow
- -$11.6M
- Return on equity
- -160.9%
- Market value
- $446.4M
- Dividend yield
- 0.0%
- Cash
- $12.5M
- Debt
- $59.0M
- Debt to equity
- 4.97
- Shares outstanding
- 34.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $100.0M | -$16.3M | -$21.5M | -$0.66 | -$11.3M | 10-K filed 3 Mar 2026 |
| FY2024 | 31 Dec 2024 | $79.9M | -$21.7M | -$27.1M | -$0.93 | -$18.3M | 10-K filed 4 Mar 2025 |
| FY2023 | 31 Dec 2023 | $65.4M | -$27.2M | -$33.0M | -$1.27 | -$19.9M | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $45.5M | -$40.8M | -$47.1M | -$1.91 | -$37.5M | 10-K filed 2 Mar 2023 |
| FY2021 | 31 Dec 2021 | $45.2M | -$23.7M | -$36.1M | -$2.17 | -$25.0M | 10-K filed 10 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $22.8M | -$6.2M | -$0.18 |
| Q1 FY2026 | 31 Mar 2026 | $22.1M | -$6.7M | -$0.20 |
| Q4 FY2025 | 31 Dec 2025 | $26.6M | -$2.7M | -$0.08 |
| Q3 FY2025 | 30 Sep 2025 | $27.4M | -$3.5M | -$0.11 |
| Q2 FY2025 | 30 Jun 2025 | $23.5M | -$8.7M | -$0.26 |
| Q1 FY2025 | 31 Mar 2025 | $22.5M | -$6.6M | -$0.21 |
| Q4 FY2024 | 31 Dec 2024 | $21.5M | -$5.3M | -$0.18 |
| Q3 FY2024 | 30 Sep 2024 | $21.1M | -$5.5M | -$0.19 |
Company events
The newest 8-K filings of 50 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 11 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Jul 2026 | 8-K | Investor update | 7.01, 9.01 |
| 8 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 12 May 2026 | 8-K | Results | 2.02, 9.01 |
| 3 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 12 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 24 Jun 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 4 Jun 2025 | 8-K | Material agreement, Agreement ended, New debt, Investor update | 1.01, 1.02, 2.03, 7.01, 9.01 |
| 27 May 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 13 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 118 held.
| Filed | Form | Period |
|---|---|---|
| 11 Aug 2026 | 10-Q | 30 Jun 2026 |
| 11 Aug 2026 | 8-K | 11 Aug 2026 |
| 28 Jul 2026 | 8-K | 28 Jul 2026 |
| 8 Jun 2026 | 8-K | 5 Jun 2026 |
| 12 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 31 Mar 2026 |
| 21 Apr 2026 | ARS | 31 Dec 2025 |
| 21 Apr 2026 | DEFA14A | – |
| 21 Apr 2026 | DEF 14A | 5 Jun 2026 |
| 3 Mar 2026 | S-8 | – |
| 3 Mar 2026 | 10-K | 31 Dec 2025 |
| 3 Mar 2026 | 8-K | 3 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 19 Jun 2026 | Geiger Uri, Director | Took pay in stock | 789 | $15.63 | $12.3K | – | 22 Jun 2026 |
| 19 Jun 2026 | Fischer Frank M, Director | Took pay in stock | 1,467 | $15.63 | $22.9K | – | 22 Jun 2026 |
| 19 Jun 2026 | Kumar Rakhi, Director | Took pay in stock | 989 | $15.63 | $15.5K | – | 22 Jun 2026 |
| 20 Mar 2026 | Geiger Uri, Director | Took pay in stock | 913 | $13.00 | $11.9K | – | 24 Mar 2026 |
| 20 Mar 2026 | Lacob Joseph, Director | Took pay in stock | 865 | $13.00 | $11.2K | – | 24 Mar 2026 |
| 20 Mar 2026 | Kumar Rakhi, Director | Took pay in stock | 1,153 | $13.00 | $15.0K | – | 23 Mar 2026 |
| 20 Mar 2026 | Fischer Frank M, Director | Took pay in stock | 1,826 | $13.00 | $23.7K | – | 23 Mar 2026 |
| 15 Dec 2025 | Morrell Martha, CHIEF MEDICAL OFFICER | Sale outside a trading plan | 25,000 | $15.97 | $399.3K | 49,964 | 4 Mar 2026 |
| 19 Dec 2025 | Lacob Joseph, Director | Took pay in stock | 678 | $16.59 | $11.2K | – | 23 Dec 2025 |
| 19 Dec 2025 | Kumar Rakhi, Director | Took pay in stock | 904 | $16.59 | $15.0K | – | 23 Dec 2025 |
| 19 Dec 2025 | Geiger Uri, Director | Took pay in stock | 715 | $16.59 | $11.9K | – | 23 Dec 2025 |
| 19 Dec 2025 | Fischer Frank M, Director | Took pay in stock | 1,431 | $16.59 | $23.7K | – | 23 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 15 Dec 2025 | MARTHA J MORRELL, Officer | 25,000 | $404.8K | 15 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 4 Sep 2026 | First Light Asset Management, LLC | 13G amended | 12.25% | 4.2M |
| 14 Aug 2026 | OrbiMed Advisors LLC | 13G amended | 4.4% | 1.5M |
| 15 May 2026 | First Light Asset Management, LLC | 13G | 8.67% | 3.0M |
| 15 May 2026 | OrbiMed Advisors LLC | 13G amended | 6.2% | 2.1M |
| 7 Nov 2025 | Soleus Private Equity Fund I, L.P. | 13G amended | 8.9% | 3.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 886.2K | -1.93% | 8.27 |
| 30 Sep 2026 | 903.6K | -5.5% | 6.18 |
| 15 Sep 2026 | 956.2K | +4.92% | 8.71 |
| 31 Aug 2026 | 911.4K | +7.81% | 6.28 |
| 14 Aug 2026 | 845.4K | +2.83% | 3.34 |
| 31 Jul 2026 | 822.1K | -5.97% | 3.94 |
| 15 Jul 2026 | 874.3K | -2.7% | 5.7 |
| 30 Jun 2026 | 898.6K | +46.63% | 3.93 |
Funds that hold it
From each fund's latest Form 13F.
130 funds held it at 30 Jun 2026: 63 added and 36 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Polar Capital Holdings Plc | 3,298,104 | $52.4M | 0 |
| Soleus Capital Management, L.P. | 2,911,122 | $46.3M | -21,085 |
| First Light Asset Management, LLC | 2,861,167 | $45.5M | +401,201 |
| Morgan Stanley | 2,654,391 | $42.2M | +87,552 |
| BlackRock, Inc. | 2,477,603 | $39.4M | +131,270 |
| Orbimed Advisors LLC | 1,505,125 | $23.9M | -591,402 |
| Driehaus Capital Management LLC | 1,447,391 | $23.0M | -4,220 |
| Vanguard Capital Management LLC | 1,227,072 | $19.5M | +103,361 |
| Deutsche Bank AG | 938,919 | $14.9M | +6,829 |
| Armistice Capital, LLC | 692,000 | $11.0M | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B